New agent draws a bead on colorectal cancer

March 8, 2004

The FDA recently approved cetuximab (Erbitux, ImClone Systems) for use in combination with irinotecan (Camptosar, Pfizer) for the treatment of epidermal growth factor receptor-1 (EGFR-1)-expressing, metastatic CRC in patients who are refractory to irinotecan-based chemotherapy. Cetuximab was also approved for use as monotherapy for the treatment of EGFR-1-expressing, metastatic CRC in those who are intolerant of irinotecan-based chemotherapy.